Compare Citius Pharmaceuticals Inc (CTXR) vs ProShares UltraShort Bloomberg Natural Gas ETF (KOLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs ProShares UltraShort Bloomberg Natural Gas ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.73 (market cap $20.01M), while ProShares UltraShort Bloomberg Natural Gas ETF trades at $28.39. The key difference: ProShares UltraShort Bloomberg Natural Gas ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | KOLD | |
|---|---|---|
Market Cap | $20.01M | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $1.82 | $49.39 |
52-Week Low | $0.48 | $13.58 |
Enterprise Value | $16.23M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.68, up 6.28% today, with a bullish technical signal from moving averages. The company shows strong commercial momentum with LYMPHIR cancer treatment revenue reaching $5.6 million in H1 2026, though it remains unprofitable with a -823% net margin. Analyst consensus is strongly bullish with 83% buy ratings.
The outlook depends on LYMPHIR's commercial success offsetting deep losses. Near-term catalysts include expanded market access and combination therapy data, but high cash burn and execution risks require monitoring. The stock offers speculative growth potential in oncology but carries significant financial risk.
KOLD, trading at $31.22, is down 2.19% over the past 24 hours. The technical outlook is bullish based on moving averages, with key support at $30 and resistance at $32. Recent news highlights natural gas market volatility, with futures influenced by weather forecasts and LNG export flows. Financial ratios are unavailable in the provided data, limiting fundamental assessment.
The stock's near-term trajectory hinges on natural gas price movements and demand shifts. While technical indicators suggest upward momentum, the lack of fundamental data and exposure to commodity price swings present risks. Investors should weigh the ETF's leveraged structure against market volatility for tactical positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About ProShares UltraShort Bloomberg Natural Gas ETF
KOLD is an inverse leveraged ETF that seeks to provide two times (2x) the inverse daily performance of the Bloomberg Natural Gas Subindex. It is designed for investors looking to profit from falling natural gas prices.
Read more on KOLD →
